Jasmeet Singh

TL;DR: The CRISPR-based DETECTR assay provides a visual and faster alternative to the US Centers for Disease Control and Prevention SARS-CoV-2 real-time RT–PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement.

TL;DR: The development of SARS-CoV-2 DETECTR is reported, a rapid (~30 min), low-cost, and accurate CRISPR-Cas12 based lateral flow assay for detection of SARs-CoVs, and it is demonstrated comparable performance to the US CDC Sars-Cov-2 real-time RT-PCR assay.

TL;DR: In this paper, the authors describe devices, systems, fluidic devices, kits, and methods for detection of target nucleic acids associated with diseases, cancers, genetic disorders, a genotype, a phenotype, or ancestral origin.

TL;DR: In this article, the authors present compositions, kits, and methods related to improved Cas activity through compositions and kits disclosed herein and practice of methods disclosed herein, one attains improved Cas protein activity such as Cas12 activity relative to Cas proteins in the state of the art such as LbCas12.

TL;DR: In this paper , a multivariable logistic regression model was used to identify factors that were independently associated with the probability of receiving chemotherapy, with a median age of 74.5 years (range 70-96).